BTIG Reiterates Buy Rating on Bicara Therapeutics Inc (BCAX)

January 15, 2026 9:04 AM EST Send to a Friend
BTIG analyst Jeet Mukherjee reiterated a Buy rating and $28.00 price target on Bicara Therapeutics Inc (NASDAQ: BCAX).The analyst commented ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login